Hua Medicine Ltd. is a biotechnology company specializing in the development and commercialization of innovative drug therapies, primarily targeting diabetes and related metabolic diseases. Headquarte... Hua Medicine Ltd. is a biotechnology company specializing in the development and commercialization of innovative drug therapies, primarily targeting diabetes and related metabolic diseases. Headquartered in Shanghai, the company leverages global resources and collaborations to address unmet medical needs worldwide. Its flagship product, dorzagliatin, is an oral treatment designed to regulate glucose homeostasis in patients with Type 2 diabetes by activating glucokinase, the glucose sensor in the body. This unique therapeutic approach aims to restore natural insulin secretion and improve overall glucose control, particularly benefiting individuals with impaired renal function. Hua Medicine's research-driven pipeline emphasizes cutting-edge pharmaceutical solutions, contributing to advancements in diabetes care and signaling China's growing influence in global pharmaceutical innovation. Beyond its core focus, the company continually explores new therapeutic fields and market opportunities to expand its impact within the healthcare sector.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Hua Medicine is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Hua Medicine is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Hua Medicine's data?

Start your 30-day free trial to request a data review for Hua Medicine.

Start Free Trial

Legal Center Contact Us